Carregant...

Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are increasingly used for advanced lung cancer, but few studies have reported on patient-reported outcomes (PROs) outside the context of a clinical trial. The goal of the current study was to assess PROs in patients participating in the GO(2) Found...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Jim, Heather S. L., Eisel, Sarah L., Hoogland, Aasha I., Shaw, Sandra, King, Jennifer C., Dicker, Adam P.
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7795027/
https://ncbi.nlm.nih.gov/pubmed/33396286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13010103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!